全文获取类型
收费全文 | 1160篇 |
免费 | 36篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 11篇 |
妇产科学 | 53篇 |
基础医学 | 65篇 |
口腔科学 | 21篇 |
临床医学 | 96篇 |
内科学 | 348篇 |
皮肤病学 | 6篇 |
神经病学 | 75篇 |
特种医学 | 44篇 |
外科学 | 229篇 |
综合类 | 6篇 |
预防医学 | 34篇 |
眼科学 | 59篇 |
药学 | 87篇 |
肿瘤学 | 55篇 |
出版年
2023年 | 4篇 |
2022年 | 6篇 |
2021年 | 32篇 |
2020年 | 24篇 |
2019年 | 39篇 |
2018年 | 38篇 |
2017年 | 32篇 |
2016年 | 32篇 |
2015年 | 25篇 |
2014年 | 37篇 |
2013年 | 58篇 |
2012年 | 80篇 |
2011年 | 85篇 |
2010年 | 54篇 |
2009年 | 66篇 |
2008年 | 103篇 |
2007年 | 102篇 |
2006年 | 93篇 |
2005年 | 79篇 |
2004年 | 59篇 |
2003年 | 43篇 |
2002年 | 59篇 |
2001年 | 6篇 |
2000年 | 7篇 |
1999年 | 4篇 |
1998年 | 4篇 |
1997年 | 7篇 |
1996年 | 5篇 |
1995年 | 6篇 |
1994年 | 1篇 |
1992年 | 1篇 |
1991年 | 3篇 |
1990年 | 1篇 |
1983年 | 3篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1979年 | 3篇 |
1969年 | 1篇 |
排序方式: 共有1204条查询结果,搜索用时 250 毫秒
21.
22.
23.
24.
Maltezou HC Maragos A Raftopoulos V Karageorgou K Halharapi T Remoudaki H Papadimitriou T Pierroutsakos IN 《Scandinavian journal of infectious diseases》2008,40(3):266-268
The aim of the current study was to investigate the contribution of various strategies to increase influenza vaccine uptake among health care workers (HCWs) working in hospitals in Greece during the 2005-2006 season. A total of 132 Greek public hospitals participated in the study. The mean HCWs vaccination rate against influenza during 2005-2006 was 16.36% compared with 1.72% during the previous season. Logistic regression analysis showed that the implementation of the following strategies was significantly associated with influenza vaccination rates above the mean vaccination rate: a mobile vaccination team (OR 2.942, 95% CI 1.154-5.382, p-value 0.016) and lectures on influenza and influenza vaccine (OR 2.386, 95% CI 0.999-5.704, p-value 0.036). In conclusion, in Greece influenza vaccination rates among HCWs remain low; however, the implementation of specific strategies was associated with increased vaccine uptakes. 相似文献
25.
26.
27.
Aurigemma GP Devereux RB Wachtell K Palmieri V Boman K Gerdts E Nieminen MS Papademetriou V Dahlöf B 《American journal of hypertension》2003,16(3):180-186
BACKGROUND: Whether to include only those patients who have not had prior hypertension treatment in clinical trials of left ventricular (LV) mass reduction is controversial. Accordingly, our aim was to study the relationship between prior treatment and both baseline and 1-year echocardiographic LV mass in subjects enrolled in the Losartan Intervention For Endpoint reduction (LIFE) study. METHODS: We studied clinical and baseline echocardiographic data on 960 patients with electrocardiographically confirmed left ventricular hypertrophy enrolled in the electrocardiographic substudy of the LIFE study, 847 of whom had LV mass remeasured after 1 year of blinded treatment. The majority (75%) of these patients had prior medical treatment for hypertension. RESULTS: In multivariable regression analysis, controlling for age, sex, blood pressure (BP), body mass index, and indices of pump and myocardial function, prior antihypertensive treatment was not associated with either greater LV mass or relative wall thickness on the baseline study. Moreover, there was no significant difference between the 637 subjects who were previously treated and the 210 who were not treated with regard to the mean reduction in systolic or diastolic pressures (-25 +/- 17 v -24 +/- -16 and -13 +/- 9 mm Hg v -12 +/- 9 mm Hg), LV mass (-27 +/- 38 v -29 +/- 34 g), or LV mass/body surface area (-14 +/- 20 v -15 +/- 18 g/m(2)), all P >.05. CONCLUSIONS: Prior treatment is not associated with either greater LV mass or greater relative wall thickness when age, body mass index, sex, systolic BP, heart rate, or indices of LV volume load and systolic function are taken into account. In addition, prior treatment is not associated with lesser degrees of LV mass reduction. For design of future clinical trials, restriction of inclusion criteria to only previously untreated patients does not appear to be necessary when the selection criterion is electrocardiographically determined left ventricular hypertrophy. 相似文献
28.
Ioannis Bellos Vasilios Pergialiotis Dimitrios Loutradis Georgios Daskalakis 《Journal of clinical hypertension (Greenwich, Conn.)》2020,22(5):826-834
This meta‐analysis aims to compare serum uric acid levels among preeclamptic and healthy pregnant women across the various trimesters and provide a summary of the effect size of this biomarker in predicting adverse pregnancy outcomes. MEDLINE, Scopus, CENTRAL, Clinicaltrials.gov, and Google Scholar databases were systematically searched from inception. Observational studies were held eligible if they reported serum uric acid among preeclamptic and healthy pregnant women. Meta‐analysis was conducted regarding uric acid concentration, diagnostic accuracy, and association with perinatal outcomes. The credibility of evidence was appraised using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. The analysis included 196 studies, comprising 39 540 women. Preeclampsia was associated with significantly elevated uric acid levels during the 1st (mean difference [MD]: 0.21 mg/dL, 95% confidence intervals [CI]: 0.06‐0.35) trimester, 2nd (MD: 1.41 mg/dL, 95% CI: 0.78‐2.05) trimester, and 3rd (MD: 2.26 mg/dL, 95% CI: 2.12‐2.40) trimester. Higher uric acid was estimated for severe preeclampsia, eclampsia, and hemolysis, elevated liver enzymes, low platelet syndrome. The sensitivity for adverse perinatal outcome prediction ranged from 67.3% to 82.7% and the specificity from 47.7% to 70.7%. In conclusion, it is suggested that serum uric acid levels are increased in preeclampsia and can be used to predict disease severity and pregnancy complications. Future prospective studies should verify these outcomes, assess the optimal cutoffs, and incorporate uric acid to combined predicting models. 相似文献
29.
30.